surmount-1 trial tirzepatide non-diabetic weight loss lowers body for adults with obesity, regardless of disease duration SURMOUNT Clinical Trials Orals Session

Among individuals without heart failure, Tirzepatide showed associations with reduced visual issues and blindness (HR 0.56, 95% CI 0.390.81) and visual disturbances (HR 0.52, 95% CI 0.350.78) compared to Semaglutide

Randomization was stratified according to country, sex (female, male) and per cent weight reduction at the end of lead-in ( 90% to demonstrate the superiority of tirzepatide MTD to placebo, for the coprimary endpoints, each at a two-sided significance level of 0.05

The expansion of cytotoxic T cells has been found to be associated with the gastrointestinal presentation of long COVID 27

Based on the pharmacological properties of the molecule, the large peptide size, the hydrophilic backbone, the albumin-binding fatty acid chain, experts estimate absorption rates would be highly variable

Weight Reduction Following Randomized Withdrawal in Adults with Obesity or Overweight (Study 4) Overview of Study 4 Study 4 (NCT04660643) was an 88-week randomized withdrawal trial in which all patients received open-label ZEPBOUND during a 36-week lead-in period, followed by randomization to either continue ZEPBOUND or switch to placebo for 52 weeks